Mironid begins dosing in first-in-human ADPKD drug trial

On October 1, 2026, Mironid announced it had dosed the first participants in initial cohorts of its Phase 1 trial of a lead LoAc® small molecule for autosomal dominant polycystic kidney disease (ADPKD).

The first-in-human study is testing safety, tolerability and pharmacokinetics in healthy volunteers—not patients with ADPKD at this stage.

The initial single-ascending-dose portion is designed to include up to 48 participants across six sequential cohorts. Mironid said it expects to report initial data in the coming year.

The milestone follows approval of the company’s Clinical Trial Application and marks Mironid’s move into clinical-stage development. The treatment’s approach is to target elevated cyclic AMP (cAMP), a signaling pathway implicated in ADPKD cyst growth; the announcement does not establish clinical benefit or safety.